XBiotech

12/23/2024

XBiotech Pauses Rheumatology program
https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-pauses-rheumatology-program

08/23/2024

XBiotech We Believe.

XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technolo...

06/18/2024

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind,

01/04/2024

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation

11/14/2023

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

(Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

09/26/2023

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical

08/21/2023

MILESTONE ACHIEVED IN PHASE I CLINICAL TRIAL FOR HUTRUKIN™ STROKE DRUG

XBiotech

08/08/2023

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved

05/22/2023

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix...

05/17/2023

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tende...

04/26/2023

XBiotech Submits New Non-clinical Safety and Pharmacodynamic Data to the FDA in Support of Natrunix Therapy

XBiotech

04/17/2023

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke AUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to